In the past week, AUPH stock has gone down by -0.37%, with a monthly decline of -13.04% and a quarterly surge of 10.50%. The volatility ratio for the week is 3.21%, and the volatility levels for the last 30 days are 3.91% for Aurinia Pharmaceuticals Inc The simple moving average for the last 20 days is -1.47% for AUPH’s stock, with a simple moving average of 18.24% for the last 200 days.
Is It Worth Investing in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Right Now?
Moreover, the 36-month beta value for AUPH is 1.23. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AUPH is 128.78M and currently, short sellers hold a 5.81% of that float. On January 31, 2025, AUPH’s average trading volume was 1.45M shares.
AUPH) stock’s latest price update
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has experienced a decline in its stock price by -1.72 compared to its previous closing price of 8.14. However, the company has seen a fall of -0.37% in its stock price over the last five trading days. zacks.com reported 2025-01-22 that Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at -7.57% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.02% of loss for the given period.
Volatility was left at 3.91%, however, over the last 30 days, the volatility rate increased by 3.21%, as shares sank -12.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.96% lower at present.
During the last 5 trading sessions, AUPH fell by -0.37%, which changed the moving average for the period of 200-days by +56.86% in comparison to the 20-day moving average, which settled at $8.12. In addition, Aurinia Pharmaceuticals Inc saw -10.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from TANG KEVIN, who purchase 500,000 shares at the price of $9.09 back on Dec 09 ’24. After this action, TANG KEVIN now owns 8,429,500 shares of Aurinia Pharmaceuticals Inc, valued at $4,545,000 using the latest closing price.
TANG KEVIN, the Director of Aurinia Pharmaceuticals Inc, purchase 400,000 shares at $9.01 during a trade that took place back on Dec 06 ’24, which means that TANG KEVIN is holding 7,929,500 shares at $3,604,000 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.87 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -0.1. The total capital return value is set at -0.04. Equity return is now at value -5.78, with -4.08 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 0.33. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -4.06.
Currently, EBITDA for the company is -63.05 million with net debt to EBITDA at 39.83. When we switch over and look at the enterprise to sales, we see a ratio of 5.43. The receivables turnover for the company is 6.04for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
To wrap up, the performance of Aurinia Pharmaceuticals Inc (AUPH) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
